This study focuses on people who have been diagnosed with estrogen receptor-positive (ER+)/HER2-negative breast cancer that cannot be removed surgically, has come back, or has spread to other areas of the body, and/or has grown after receiving hormone-blocking treatments. The purpose of the study is to evaluate the safety and effectiveness of the combination of 2 drugs, belzutifan (an experimental oral medication also known as MK-6482) plus fulvestrant in these patients. Researchers will compare belzutifan plus fulvestrant to everolimus (oral medication approved by the U.S. Food and Drug Administration) plus an endocrine therapy, either exemestane or fulvestrant (selected by the study doctor). Procedures include physical exam, imaging scans, blood and urine sample collection, tumor biopsies and drug administration. Participants will be randomly assigned to 1 of 2 groups. Group 1 will receive belzutifan plus fulvestrant. Group 2 will receive everolimus plus an endocrine therapy (fulvestrant or exemestane).
What is the full name of this clinical trial?
MK-6482-029: A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous Endocrine Therapy